AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
82.00
+0.28 (0.34%)
Nov 4, 2025, 12:15 PM EST - Market open
AstraZeneca Employees
AstraZeneca had 92,900 employees as of December 31, 2024. The number of employees increased by 3,000 or 3.34% compared to the previous year.
Employees
92,900
Change (1Y)
3,000
Growth (1Y)
3.34%
Revenue / Employee
$608,192
Profits / Employee
$89,290
Market Cap
252.04B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 92,900 | 3,000 | 3.34% |
| Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
| Dec 31, 2022 | 83,500 | 400 | 0.48% |
| Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
| Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
| Dec 31, 2019 | 70,600 | 6,000 | 9.29% |
| Dec 31, 2018 | 64,600 | 3,500 | 5.73% |
| Dec 31, 2017 | 61,100 | 1,400 | 2.35% |
| Dec 31, 2016 | 59,700 | -1,800 | -2.93% |
| Dec 31, 2015 | 61,500 | 4,000 | 6.96% |
| Dec 31, 2014 | 57,500 | 6,000 | 11.65% |
| Dec 31, 2013 | 51,500 | -200 | -0.39% |
| Dec 31, 2012 | 51,700 | -5,500 | -9.62% |
| Dec 31, 2011 | 57,200 | -3,800 | -6.23% |
| Dec 31, 2010 | 61,000 | -1,700 | -2.71% |
| Dec 31, 2009 | 62,700 | -2,300 | -3.54% |
| Dec 31, 2008 | 65,000 | -2,400 | -3.56% |
| Dec 31, 2007 | 67,400 | 600 | 0.90% |
| Dec 31, 2006 | 66,800 | 1,500 | 2.30% |
| Dec 31, 2005 | 65,300 | 1,100 | 1.71% |
| Dec 31, 2004 | 64,200 | 1,600 | 2.56% |
| Dec 31, 2003 | 62,600 | 3,400 | 5.74% |
| Dec 31, 2002 | 59,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
AZN News
- 1 day ago - AstraZeneca wins shareholder backing for NYSE listing in US pivot - Reuters
- 1 day ago - AstraZeneca wins shareholder backing for NYSE listing as drugmaker pivots to US - Reuters
- 1 day ago - BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025 - Accesswire
- 4 days ago - FTSE Index shares to watch next week: BT, BP, IAG, AstraZeneca, Marks & Spencer - Invezz
- 11 days ago - AstraZeneca found in breach of industry code over Symbicort marketing, industry body says - Reuters
- 15 days ago - AstraZeneca hails major breakthroughs with breast-cancer drugs - Market Watch
- 16 days ago - AstraZeneca's Datroway extends survival in aggressive breast cancer - Reuters
- 17 days ago - AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment - Reuters